IO BIOTECH INC. - COMMON STOCK

IO Biotech Hosting Key Opinion Leader Webinar Series

22 апр 2022 08:33:34 Источник Nasdaq GlobeNewswire

IO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial

12 апр 2022 08:30:00 Источник Nasdaq GlobeNewswire

IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting

08 апр 2022 16:15:00 Источник Nasdaq GlobeNewswire

IO Biotech Announces Year-End Results for 2021

31 мар 2022 16:15:00 Источник Nasdaq GlobeNewswire

IO Biotech Announces Acceptance of Abstract to be Presented at AACR Annual Meeting on April 8, 2022

08 мар 2022 16:30:00 Источник Nasdaq GlobeNewswire

IO Biotech to Present at 42nd Annual Cowen Healthcare Conference

04 мар 2022 08:00:00 Источник Nasdaq GlobeNewswire

IO Biotech Announces Appointment of David V. Smith to its Board of Directors

03 мар 2022 16:05:00 Источник Nasdaq GlobeNewswire

IO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicine

09 дек 2021 11:05:00 Источник Nasdaq GlobeNewswire

IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial

06 дек 2021 08:00:04 Источник Nasdaq GlobeNewswire

IO Biotech, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

09 ноя 2021 11:06:22 Источник Nasdaq GlobeNewswire